PT - JOURNAL ARTICLE AU - Bianca A.W. Hoeben AU - Johannes H.A.M. Kaanders AU - Gerben M. Franssen AU - Esther G.C. Troost AU - Paul F.J.W. Rijken AU - Egbert Oosterwijk AU - Guus A.M.S. van Dongen AU - Wim J.G. Oyen AU - Otto C. Boerman AU - Johan Bussink TI - PET of Hypoxia with <sup>89</sup>Zr-Labeled cG250-F(ab′)<sub>2</sub> in Head and Neck Tumors AID - 10.2967/jnumed.109.073189 DP - 2010 Jul 01 TA - Journal of Nuclear Medicine PG - 1076--1083 VI - 51 IP - 7 4099 - http://jnm.snmjournals.org/content/51/7/1076.short 4100 - http://jnm.snmjournals.org/content/51/7/1076.full SO - J Nucl Med2010 Jul 01; 51 AB - Hypoxic tumor cells are resistant to radiotherapy and various chemotherapeutic agents. The pretherapeutic assessment of intratumoral hypoxia may allow selection of patients for intensified treatment regimens. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related protein involved in pH regulation and is upregulated in many tumor types. Radionuclide imaging using a monoclonal antibody against CAIX, such as cG250, may allow noninvasive PET of hypoxia in these tumor types. The aims of this study were to investigate whether 89Zr-labeled cG250-F(ab′)2 allowed visualization of tumor hypoxia using small-animal PET and whether the tracer showed spatial correlation to the microscopic distribution of CAIX-expressing cells in a human head and neck xenograft tumor model. Methods: Athymic mice with subcutaneous human head and neck carcinoma xenografts (SCCNij3) were imaged with small-animal PET after injection of 89Zr-cG250-F(ab′)2. PET images were parameterized in terms of standardized uptake values (SUVs). After injection with the nitroimidazole hypoxia marker pimonidazole and the perfusion marker Hoechst 33342, the animals were sacrificed, tumors excised, and CAIX- and pimonidazole-marked hypoxia and blood perfusion were analyzed immunohistochemically. 89Zr-cG250-F(ab′)2 tumor uptake was analyzed by ex vivo activity counting and by autoradiography of tumor sections. Results: As early as 4 h after administration, accumulation of 89Zr-cG250-F(ab′)2 in the tumor had occurred and tumors were clearly visualized by PET, with reduced uptake by 24 h after injection. Pixel-by-pixel analysis showed a significant positive spatial correlation between CAIX expression and 89Zr-cG250-F(ab′)2 localization (r = 0.57–0.74; P &lt; 0.0001). Also, significant correlations were found between pimonidazole staining intensity and 89Zr-cG250-F(ab′)2 activity concentration, although less strong (r = 0.46–0.68; P &lt; 0.0001). Tumor maximum SUV correlated significantly with tumor uptake determined ex vivo (r = 0.93; P = 0.0067), as did fractions of CAIX and pimonidazole in tumor sections (r = 0.75; P = 0.03 and r = 0.78; P = 0.02, respectively). Conclusion: 89Zr-labeled cG250-F(ab′)2 small-animal PET showed rapid accumulation in a head and neck xenograft tumor model with good correlation to CAIX expression on a microscopic level.